No profile data available.
Lexeo Therapeutics, Inc. (LXEO) is a healthcare company in the cardiac treatment pharmaceuticals industry, based in New York, United States, with about 63 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$99.96 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $265.14 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.
Lexeo Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$265.14 million as of October 9, 2026.
Listed companies of a similar size in the same industry (cardiac treatment pharmaceuticals) include Cytokinetics, Incorporated (CYTK), Lexicon Pharmaceuticals, Inc. (LXRX), Cardiol Therapeutics Inc. (CRDL), Tenaya Therapeutics, Inc. (TNYA).